VaccibodyAs - Delisted Stock

VaccibodyAs is trading at 4.91 as of the 2nd of March 2024, a 6.74% increase since the beginning of the trading day. The stock's open price was 4.6. VaccibodyAs symbol was renamed from VACC to BRNS on 7th of November 2023. Equity ratings for VaccibodyAs are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of December 2023 and ending today, the 2nd of March 2024. Click here to learn more.

VaccibodyAs Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. VaccibodyAs market risk premium is the additional return an investor will receive from holding VaccibodyAs long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in VaccibodyAs. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although VaccibodyAs' alpha and beta are two of the key measurements used to evaluate VaccibodyAs' performance over the market, the standard measures of volatility play an important role as well.

Delisting Warning - VACC

VaccibodyAs was delisted

The entity VaccibodyAs with a symbol VACC was delisted from Oslo Stock Exchange. Please try Barinthus Biotherapeutics Plc with a symbol BRNS from now on. Check all delisted instruments accross multiple markets.

VaccibodyAs Corporate Management

Elected by the shareholders, the VaccibodyAs' board of directors comprises two types of representatives: VaccibodyAs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VaccibodyAs. The board's role is to monitor VaccibodyAs' management team and ensure that shareholders' interests are well served. VaccibodyAs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VaccibodyAs' outside directors are responsible for providing unbiased perspectives on the board's policies.

Still Interested in VaccibodyAs?

Investing in delisted delisted stocks can be risky, as the stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the VaccibodyAs information on this page should be used as a complementary analysis to other VaccibodyAs' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Consideration for investing in VaccibodyAs Stock

If you are still planning to invest in VaccibodyAs check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the VaccibodyAs' history and understand the potential risks before investing.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Find actively traded Exchange Traded Funds (ETF) from around the world
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance